266 related articles for article (PubMed ID: 11673754)
1. Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide.
Nüsing RM; Reinalter SC; Peters M; Kömhoff M; Seyberth HW
Clin Pharmacol Ther; 2001 Oct; 70(4):384-90. PubMed ID: 11673754
[TBL] [Abstract][Full Text] [Related]
2. Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome.
Reinalter SC; Jeck N; Brochhausen C; Watzer B; Nüsing RM; Seyberth HW; Kömhoff M
Kidney Int; 2002 Jul; 62(1):253-60. PubMed ID: 12081585
[TBL] [Abstract][Full Text] [Related]
3. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.
Catella-Lawson F; McAdam B; Morrison BW; Kapoor S; Kujubu D; Antes L; Lasseter KC; Quan H; Gertz BJ; FitzGerald GA
J Pharmacol Exp Ther; 1999 May; 289(2):735-41. PubMed ID: 10215647
[TBL] [Abstract][Full Text] [Related]
4. Selective cyclooxygenase-2 inhibition by nimesulide in man.
Cullen L; Kelly L; Connor SO; Fitzgerald DJ
J Pharmacol Exp Ther; 1998 Nov; 287(2):578-82. PubMed ID: 9808683
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
[TBL] [Abstract][Full Text] [Related]
6. The role of cyclooxygenases and prostanoid receptorsin furosemide-like salt losing tubulopathy: the hyperprostaglandin E syndrome.
Nüsing RM; Seyberth HW
Acta Physiol Scand; 2004 Aug; 181(4):523-8. PubMed ID: 15283766
[TBL] [Abstract][Full Text] [Related]
7. Dominant role of prostaglandin E2 EP4 receptor in furosemide-induced salt-losing tubulopathy: a model for hyperprostaglandin E syndrome/antenatal Bartter syndrome.
Nüsing RM; Treude A; Weissenberger C; Jensen B; Bek M; Wagner C; Narumiya S; Seyberth HW
J Am Soc Nephrol; 2005 Aug; 16(8):2354-62. PubMed ID: 15976003
[TBL] [Abstract][Full Text] [Related]
8. Role of COX-2-derived metabolites in regulation of the renal hemodynamic response to norepinephrine.
Llinás MT; López R; Rodríguez F; Roig F; Salazar FJ
Am J Physiol Renal Physiol; 2001 Nov; 281(5):F975-82. PubMed ID: 11592955
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis.
Belton O; Byrne D; Kearney D; Leahy A; Fitzgerald DJ
Circulation; 2000 Aug; 102(8):840-5. PubMed ID: 10952950
[TBL] [Abstract][Full Text] [Related]
10. Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers.
Stichtenoth DO; Marhauer V; Tsikas D; Gutzki FM; Frölich JC
Kidney Int; 2005 Nov; 68(5):2197-207. PubMed ID: 16221219
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis.
Belton OA; Duffy A; Toomey S; Fitzgerald DJ
Circulation; 2003 Dec; 108(24):3017-23. PubMed ID: 14638539
[TBL] [Abstract][Full Text] [Related]
12. In vivo selectivity of a selective cyclooxygenase 2 inhibitor in the oral surgery model.
Khan AA; Brahim JS; Rowan JS; Dionne RA
Clin Pharmacol Ther; 2002 Jul; 72(1):44-9. PubMed ID: 12152003
[TBL] [Abstract][Full Text] [Related]
13. Successful management of an extreme example of neonatal hyperprostaglandin-E syndrome (Bartter's syndrome) with the new cyclooxygenase-2 inhibitor rofecoxib.
Haas NA; Nossal R; Schneider CH; Lewin MA; Ocker V; Holder M; Uhlemann F
Pediatr Crit Care Med; 2003 Apr; 4(2):249-51. PubMed ID: 12749662
[TBL] [Abstract][Full Text] [Related]
14. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice.
Praticò D; Tillmann C; Zhang ZB; Li H; FitzGerald GA
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3358-63. PubMed ID: 11248083
[TBL] [Abstract][Full Text] [Related]
15. Hyperprostaglandin E syndrome: use of indomethacin and steroid, and death due to necrotizing enterocolitis and sepsis.
Cetinkaya M; Köksal N; Ozkan H; Dönmez O; Sağlam H; Kiriştioğlu I
Turk J Pediatr; 2008; 50(4):386-90. PubMed ID: 19014056
[TBL] [Abstract][Full Text] [Related]
16. Effects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors.
Gray PA; Warner TD; Vojnovic I; Del Soldato P; Parikh A; Scadding GK; Mitchell JA
Br J Pharmacol; 2002 Dec; 137(7):1031-8. PubMed ID: 12429575
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of cyclooxygenase-2 (COX-2) reduces prostaglandin E2 production and attenuates systemic disease sequelae in experimental pancreatitis.
Foitzik T; Hotz HG; Hotz B; Wittig F; Buhr HJ
Hepatogastroenterology; 2003; 50(52):1159-62. PubMed ID: 12846004
[TBL] [Abstract][Full Text] [Related]
18. Correction of increased prostacyclin production in Bartter's syndrome by indomethacin.
Güllner HG; Cerletti C; Bartter FC; Gill JR; Smith JB
Trans Assoc Am Physicians; 1980; 93():130-40. PubMed ID: 7018063
[No Abstract] [Full Text] [Related]
19. Effects of nimesulide and indometacin on COX-1 and COX-2: a comparative study.
de Leval X; Dogné JM; Neven P; Labasse A; Delarge J; Reginster JY; Henrotin Y
J Pharm Belg; 1999; 54(3):89-90. PubMed ID: 10431478
[TBL] [Abstract][Full Text] [Related]
20. Human pharmacology of naproxen sodium.
Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
